Neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF), are promising therapeutic agents for neurodegenerative diseases. However, the application of GDNF to treat these diseases effectively is limited because the blood–brain barrier (BBB) prevents the local delivery of macromolecular therapeutic agents from entering the central nervous system (CNS). Focused ultrasound combined with microbubbles (MBs) using appropriate parameters has been previously demonstrated to be able to open the BBB locally and noninvasively. This study investigated the targeted delivery of GDNF MBs through the BBB by magnetic resonance imaging (MRI)-guided focused ultrasound. Evans Blue extravasation and histological examination were used to determine the optimum focused ultrasound parameters. Enzyme-linked immunosorbent assay was performed to verify the effects of GDNF bound on MBs using a biotin–avidin bridging chemistry method to promote GDNF delivery into the brain. The results showed that GDNF can be delivered locally and noninvasively into the CNS through the BBB using MRI-guided focused ultrasound combined with MBs under optimum parameters. MBs that bind GDNF combined with MRI-guided focused ultrasound may be an effective way of delivering neurotrophic factors directly into the CNS. The method described herein provides a potential means of treating patients with CNS diseases.
References
[1]
Grondin R, Gash DM (1998) Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol 245: P35–42.
[2]
Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383–394.
[3]
Carnicella S, Amamoto R, Ron D (2009) Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 43: 35–43.
[4]
Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007) Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64: 1575–1579.
[5]
He DY, Ron D (2006) Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J 20: 2420–2422.
[6]
Nevalainen N, Chermenina M, Rehnmark A, Berglof E, Marschinke F, et al. (2010) Glial cell line-derived neurotrophic factor is crucial for long-term maintenance of the nigrostriatal system. Neuroscience 171: 1357–1366.
[7]
Deng CX (2010) Targeted drug delivery across the blood-brain barrier using ultrasound technique. Ther Deliv 1: 819–848.
Tempany CM, Stewart EA, McDannold N, Quade BJ, Jolesz FA, et al. (2003) MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology 226: 897–905.
[10]
Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N (2005) Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24: 12–20.
[11]
Yang FY, Fu WM, Chen WS, Yeh WL, Lin WL (2008) Quantitative evaluation of the use of microbubbles with transcranial focused ultrasound on blood-brain-barrier disruption. Ultrason Sonochem 15: 636–643.
[12]
Yang FY, Lin YS, Kang KH, Chao TK (2011) Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Control Release 150: 111–116.
[13]
Kaufmann BA, Lewis C, Xie A, Mirza-Mohd A, Lindner JR (2007) Detection of recent myocardial ischaemia by molecular imaging of P-selectin with targeted contrast echocardiography. Eur Heart J 28: 2011–2017.
[14]
Kinoshita M, McDannold N, Jolesz FA, Hynynen K (2006) Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 340: 1085–1090.
[15]
Takalkar AM, Klibanov AL, Rychak JJ, Lindner JR, Ley K (2004) Binding and detachment dynamics of microbubbles targeted to P-selectin under controlled shear flow. J Control Release 96: 473–482.
[16]
Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ (2007) Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor. Int J Pharm 344: 9–15.
[17]
Gearhart DA, Middlemore ML, Terry AV (2006) ELISA methods to measure cholinergic markers and nerve growth factor receptors in cortex, hippocampus, prefrontal cortex, and basal forebrain from rat brain. J Neurosci Methods 150: 159–173.
[18]
Carnicella S, Ron D (2009) GDNF–a potential target to treat addiction. Pharmacol Ther 122: 9–18.
[19]
Eisch AJ, Bolanos CA, de Wit J, Simonak RD, Pudiak CM, et al. (2003) Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry 54: 994–1005.
[20]
Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63: 71–124.
[21]
Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, et al. (2007) Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121: 901–907.
[22]
Jordao JF, Ayala-Grosso CA, Markham K, Huang Y, Chopra R, et al. (2010) Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS ONE 5: e10549.
[23]
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569–1572.
[24]
Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, et al. (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637–647.
[25]
Chopra R, Vykhodtseva N, Hynynen K (2010) Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. ACS Chem Neurosci 1: 391–398.
[26]
Wang F, Cheng Y, Mei J, Song Y, Yang YQ, et al. (2009) Focused ultrasound microbubble destruction-mediated changes in blood-brain barrier permeability assessed by contrast-enhanced magnetic resonance imaging. J Ultrasound Med 28: 1501–1509.
[27]
McDannold N, Vykhodtseva N, Hynynen K (2008) Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol 34: 930–937.
[28]
Kinoshita M, McDannold N, Jolesz FA, Hynynen K (2006) Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 103: 11719–11723.
[29]
Hernot S, Klibanov AL (2008) Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 60: 1153–1166.
[30]
Lum AF, Borden MA, Dayton PA, Kruse DE, Simon SI, et al. (2006) Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J Control Release 111: 128–134.
